Active Not RecruitingNCT05737693
Intensive trauma therapy with ketamine or midazolam for trauma symptoms
About this title
Read the official source — NCT05737693Medication studyAges 21–70United States + IsraelPTSD
Understand this study
Who could participate?
Listed age limits: 21 years to 70 years.
- Listed locations
- New Haven and 1 more locationSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: August 21, 2023
- Recruitment status
- Active Not Recruiting
- Enrollment listed in the registry
- 350
- Sponsor
- Yale University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, Israel
- Age range
- From 21 Years to 70 Years
- Official registry ID
- NCT05737693
- Official title
Show the full official title
Posttraumatic Stress Disorder (PTSD) Treatment: Using Ketamine to Enhance Memory Reconsolidation and Extinction of Overgeneralized Fear in Individuals Diagnosed With PTSD
Recruitment & locations
Not recruitingThis badge reflects the study status reported by the registry. Check the registry for the latest information.
New Haven, United States · Tel Aviv, Israel
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Yale University, a university.
Does this study involve medication?
Yes. The study involves medication, including ketamine and Midazolam.
Who can participate?
Listed age limits: 21 years to 70 years.
Is this study still recruiting?
The registry lists this study as active, but no longer recruiting.
